Cita APA (7a ed.)

NS, J., YT, T., KC, A., & S, L. (2021). Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. Dove Medical Press.

Cita Chicago Style (17a ed.)

NS, Joseph, Tai YT, Anderson KC, y Lonial S. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. Dove Medical Press, 2021.

Cita MLA (8a ed.)

NS, Joseph, et al. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. Dove Medical Press, 2021.